Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;79(8):373-382.
doi: 10.1002/ddr.21461. Epub 2018 Oct 21.

Dose translation between laboratory animals and human in preclinical and clinical phases of drug development

Anroop Nair  1 , Mohamed Aly Morsy  1   2 , Shery Jacob  3
Affiliations

Dose translation between laboratory animals and human in preclinical and clinical phases of drug development

Anroop Nair et al. Drug Dev Res. 2018 Dec.

Abstract

Preclinical Research & Development Appropriate translation and determination of the maximum recommended starting dose in human is a vital task in new drug development and research. Allometric scaling is the most frequently used approach for dose extrapolation based on normalization of dose-to-body surface area. Misinterpretation of allometric dose conversion and safety factor application can lead to major problems in calculating maximum recommended safe starting dose in first-in-human clinical trials. Therefore, dose translation always necessitates careful consideration of body surface area, pharmacological, physiological and anatomical factors, pharmacokinetic parameters, metabolic function, receptor, and life span. The concept of estimating the first-in-human dose, interspecies scaling between species and the factors influencing the dose escalation were reviewed. The pros and cons of various approaches to determine first-in-human dose including allometric scaling, pharmacokinetically guided approach, minimal anticipated biological effect level, pharmacokinetic-pharmacodynamic modeling, similar drug approach, and microdosing were explained. The five steps to estimate maximum recommended starting dose for human studies by scaling factor were elaborated. Few examples, illustrating the application of different approaches were also demonstrated along with concerns that may be considered while applying such methods. Furthermore, typical considerations in dose administration, dosing through diet, maximum absorbable dose, blood sampling, and anesthesia in animal species were discussed. In summary, this review may serve as a concise guide for predicting human equivalent dose from animal species for researchers involved in various phases of preclinical and early clinical drug development.

Keywords: allometric scaling; dose administration; dose conversion.

PubMed Disclaimer

References

REFERENCES

    1. American Society of Laboratory Animal Practitioners. (1991). SYNAPSE, 24.
    1. Banavar, J. R., Moses, M. E., Brown, J. H., Damuth, J., Rinaldo, A., Sibly, R. M., & Maritan, A. (2010). A general basis for quarter-power scaling in animals. Proceedings of the National Academy of Sciences of the United States of America, 107(36), 15816-15820.
    1. Carbone, L., & Austin, J. (2016). Pain and laboratory animals: Publication practices for better data reproducibility and better animal welfare. PLoS ONE, 11(5), e0155001.
    1. Chaturvedi, P. R., Decker, C. J., & Odinecs, A. (2001). Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Current Opinion in Chemical Biology, 5(4), 452-463.
    1. Contrera, J. F., Matthews, E. J., Kruhlak, N. L., & Benz, R. D. (2004). Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Regulatory Toxicology and Pharmacology, 40(3), 185-206.

LinkOut - more resources